Erschienen in:
22.02.2019 | Original Article
Risk factors affecting hospital stay among patients undergoing colon cancer surgery: a prospective cohort study
verfasst von:
Miren Orive, Urko Aguirre, Nerea Gonzalez, Santiago Lázaro, Maximino Redondo, Marisa Bare, Rocío Anula, Eduardo Briones, Antonio Escobar, Cristina Sarasqueta, Susana Garcia-Gutierrez, José M. Quintana, for the REDISSEC-CARESS/CCR group
Erschienen in:
Supportive Care in Cancer
|
Ausgabe 11/2019
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To identify and validate risk factors that contribute to prolonged length of hospital stay (LOS) in patients undergoing resection for colorectal cancer.
Methods
This prospective cohort study included 1955 patients admitted to 22 hospitals for primary resection of colorectal cancer. Multivariate analyses were used to identify and validate risk factors, randomizing patients into a derivation and a validation cohort. Multiple correspondence and cluster analysis were performed to identify clinical subtypes based on LOS.
Results
The strongest independent predictors of prolonged LOS were postoperative reintervention, surgical site infection, open surgery, and distant metastasis. The multiple correspondence and cluster analysis provided three groups of patients in relation to prolonged LOS: patients with the longest LOS included the highest percentage of patients with open surgery, distant metastasis, deep surgical site infections, emergency admissions, additional diagnostic factors, and highly contaminated surgical sites. Patients with prolonged LOS (> 14 days) were more likely to develop adverse outcomes within 30 days after discharge.
Conclusions
Patients undergoing resection of colorectal cancer cluster into different groups based on LOS of the index admission. Those with prolonged LOS were more likely to develop adverse outcomes within 30 days after discharge. Some of the strongest independent predictors of prolonged LOS, such as surgical infections or open surgery, could be modified to reduce LOS and, in turn, other adverse outcomes.
Trial registration
NCT02488161